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ABSTRACT
Introduction: In patients affected by insulin
resistance (IR), metformin (MET) therapy has
been shown to exert its positive effects by
improving glucose tolerance and preventing
the evolution to diabetes. Recently, it was
shown that the addition of metformin to
physical training did not improve sensitivity
to insulin or peak oxygen consumption (peak
VO2). The purpose of this study was to establish
the effect of metformin and exercise, separately
or in combination, on systolic left ventricular
(LV) function in individuals with IR.
Methods: Seventy-five patients with IR were
enrolled and subsequently assigned to MET,
combination MET and exercise, or exercise
alone. The LV systolic and diastolic functions
were evaluated with standard echocardiography
tissue Doppler imaging (TDI) and speckle
tracking echocardiography at baseline and
after 12 weeks of treatment.
Results: MET, administered alone or in
association with exercise, improved
longitudinal LV function, as evidenced by an
increase in systolic (S) wave on TDI, alongside
increases in longitudinal global strain and strain
rate in comparison to the group undergoing
physical training alone. The traditional
echocardiographic parameters showed no
statistically significant differences among the
three groups before or after the different cycles
of therapy.
Conclusions: Treatment with MET, either with
or without exercise, but not exercise alone,
produced a significant increase in global
longitudinal LV systolic function at rest. These
findings validate the observation that the use of
MET alone or in association with exercise has a
crucial role to counteract the negative effects of
IR on cardiovascular function.
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INTRODUCTION
Insulin resistance (IR) is a condition
characterized by normal hormone levels
producing a sub-optimal biological response,
and is considered to be a major etiologic factor
in the genesis of non-ischemic heart failure [1].
Therefore, IR leads to a specific myocardial
myopathy in which the heart is unable to
adequately respond to external stressors by
modifying substrate metabolism to increase its
energy efficiency. Evidence from several studies
determined that IR is crucial in the evolution
towards a reduction in cardiovascular
performance [2], and is a strong prognostic
factor for the subsequent progression to heart
failure, independently of all other known
cardiovascular risk factors, including diabetes
mellitus [3, 4].
The US Diabetes Prevention Program (DPP)
showed that changes in lifestyle (i.e., eating a
low-fat diet and increasing physical activity)
and medical treatment with an
insulin-sensitizing drug, such as metformin
(MET) reduces the evolution from IR to
diabetes mellitus [5]. In a selected population
with pre-diabetes, the use of medical treatment
with MET has been suggested by several
international scientific societies [6, 7].
However, MET proved to have some collateral
negative effects, such as a significant reduction
in oxygen consumption, both in healthy
individuals [8] and in IR subjects [9].
Exercise training and MET recently proved to
increase insulin sensitivity after 3 months of
treatment in a population with pre-diabetes.
However, the addition of MET appeared to
dampen the effect of exercise [10]. In a
previous study, we showed a significant
increase in peak oxygen consumption (peak
VO2) after 12 weeks of exercise alone or in
combination with MET, whereas MET alone
resulted in no improvement in peak VO2 [11].
Speckle tracking echocardiography (STE)
permits the detection of an early subclinical
impairment of myocardial function [12]. Using
this echocardiographic technique, a reduction
in systolic left ventricular (LV) contractile
reserve was demonstrated in patients with IR
during a physical exercise test [13] or
dobutamine stress echocardiography [14].
The aim of the present study was to evaluate
a population with IR using STE at baseline and
after 3 months of therapy with MET or physical
exercise, administered separately or together.
The hypothesis of the study was that in IR
patients, MET alone or in combination with
physical exercise, could prove to exert positive
effects on systolic function, as already shown in
heart failure patients.
METHODS
Study Design and Participants
Male and female subjects were consecutively
recruited from individuals screened at the
Diabetic Center at our University Hospital
(University of Cagliari). No sponsorship was
received to perform the study. The study was
spontaneous and blinded to the investigators.
All of the patients presented with recently
identified impaired glucose tolerance (IGT),
defined as 2 h values in the oral glucose
tolerance test (OGTT) of 140–199 mg/dL and/
or impaired fasting glucose (IFG), defined as
fasting glucose levels of 100–125 mg/dL. OGTT
was performed to assess glucose and insulin in
the fasting state and every 30 min up to 2 h after
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ingesting a glucose load (75 g). All of the
subjects enrolled were affected by IR, defined
according to the values of the homeostatic
model assessment (HOMA) index ([2.77)
described by Bonora et al. [15].
The inclusion criteria for all IR patients were
as follows: age 20–55 years, echocardiographic
LV ejection fraction (LVEF) C55%; absence of
LV wall motion abnormalities; and normal
renal and hepatic function (bilirubin B1.5 mg/
dL, creatinine B2.0 mg/dL). The exclusion
criteria were: current smoker; presence of
diabetes; hypertension with LV hypertrophy;
obesity (overweight patients were accepted with
body mass index\29.9 kg/m2); atrial fibrillation
or severe arrhythmias; and moderate-to-severe
heart valve disease. Patients with hypertension
without LV hypertrophy or dyslipidemia were
included in the study.
Study Protocol
At enrollment, all of the subjects underwent a
physical examination, 12-lead
electrocardiogram, standard cardiopulmonary
(CP) exercise test (CPET), complete blood
chemistry, standard echocardiography
(M-mode, 2D and Doppler), tissue Doppler
imaging (TDI) and evaluation of global
longitudinal strain (GLS) and global
longitudinal strain rate (GLSR) parameters
with STE. All of the patients were subsequently
allocated to the three treatment groups (1:1:1)
and re-evaluated after 12 weeks: Group M
received 12 weeks of MET treatment; Group Ex
received 12 weeks of supervised exercise
therapy; and Group MEx received 12 weeks of
MET therapy plus supervised exercise. Patients
receiving therapy with MET started treatment at
a dose of 500 mg/day. The dose was increased to
the clinical dose of 1000 mg/day in the second
week. This dose was administered for the
remaining 11 weeks of the study.
Standard and TDI Echocardiography
Using a commercially available system (Toshiba
ArtidaTM; Toshiba Corp., Tochigi, Japan),
echocardiographic images were recorded. LVEF
was obtained according to biplane Simpson’s
rule and considered abnormal at \55%. From
the four-chamber view, a pulsed wave Doppler
(PWD) examination of the LV inflow was
performed. The sample volume was placed
between the mitral leaflet tips to evaluate the
early (E) and late (A) diastolic peak velocities.
The E/A ratio was derived and deceleration time
(DecT) of the E wave was measured.
Speckle Tracking Echocardiography (STE)
A four- and two-chamber view clip was acquired
at each evaluation. The longitudinal ventricular
function at baseline and after exercise was
calculated offline using raw data (Toshiba
Corp., Tochigi, Japan). GLS and GLSR were
obtained by averaging the strain and strain rate
of all LV segments in the four-chamber and
two-chamber view.
To achieve homogeneous acquisition of data
and images, all of the echocardiographic
examinations were performed by the same
operator (C.C.). All of the offline
measurements were performed by a single
investigator (M.D.) who was blinded to the
clinical condition of the study participants. The
intra-observer variability in our laboratory has
been documented previously [16].
Exercise Training Protocol
The same exercise training protocol was
performed in both the exercise groups (Ex and
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MEx). The training program encompassed
stretching exercises, and warm-up, central and
cool down phases. The central phase included
cycle ergometer training at the anaerobic
threshold level, which was performed for
60 min/day four times per week for 12 weeks
at our laboratory. After 6 weeks, each subject
underwent a CPET to readjust the training
workload [17].
Statistical Analysis
For the anthropometric and clinical
characteristics of the three groups, continuous
variables were compared using repeated
measures analysis of variance (ANOVA).
Categorical variables were analyzed with
Fisher’s exact test. Differences in
echocardiographic data were also evaluated
using ANOVA. A Bonferroni-corrected
two-tailed P\0.05 was considered statistically
significant.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation (ethics
committees of the University of Cagliari, Italy)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients prior to inclusion in the study.
RESULTS
The study enrolled 75 patients (35 males and 40
females) with a mean [±standard deviation
(SD)] age of 46 (±11) years. Twenty-five
patients were included in each of the three
treatment groups. Our population was
characterized by a mean (±SD) HOMA index
of 5.48 (±3.8), an increased body weight and a
reduced mean (±SD) peak VO2 61.83 ± 12%) in
comparison with theoretical values of a healthy
population comparable for age and
anthropometric characteristics (Table 1). There
were no between-group differences with regard
to anthropometric parameters, insulin
sensitivity, and cardiovascular risk factors
(Table 2). Five subjects from the Ex group and
four from the MEx group were excluded from
the final analysis due to their inability to
regularly carry out the physical training
program (training attendance\70%).
Conventional echocardiography revealed
normal cardiac chamber size, left ventricular
mass and ejection fraction in all patients
(Table 3). Diastolic function measured using
pulsed Doppler and TDI showed a slight initial
diastolic dysfunction when compared with
normal values [18]. The systolic function
parameters presented as the GLS and GLSR
results were consistent with the reference
values obtained for healthy populations [19].
The variation in the principal
echocardiographic parameters at enrollment
and at the 12-week follow-up, and the
differences between groups are shown in
Table 4. MET alone or in association with
exercise training (Groups M and MEx,
respectively) resulted in improvements in the
longitudinal left ventricular S wave, GLS and
GLSR compared with the Ex Group. Standard
echocardiographic parameters did not differ
statistically between the groups at baseline or
at the 12-week follow-up. Improvements were
observed in the S wave, GLS and GLSR in both
the M group than the MEx group (Table 5). In
the Ex group, none of the examined
echocardiographic parameters changed from
baseline to post-treatment period (Table 5).
However, we observed a trend towards
improvement in diastolic function based on a
reduction of the end-diastolic filling pressures
(E/E0) in all three treatment groups (Table 5).
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DISCUSSION
In the present study, we examined the effects of
12 weeks of MET and exercise treatment,
separately or in combination, on LV
contractile function in a population of
patients with IR. In patients with IR, treatment
with MET, alone or in association with physical
exercise, produced a significant improvement in
global longitudinal LV systolic function at rest,
as highlighted by speckle tracking and TDI
analysis. Also, exercise alone did not improve
the above parameters for LV systolic function.
Insulin-resistant Cardiomyopathy
In humans, most reports in the literature
investigating IR and cardiac dysfunction refer
to the deterioration of diastolic function [20,
21]. However, IR can lead to impaired
myocardial systolic function, potentially
through altered calcium homeostasis,
increased oxidative stress, altered substrate
metabolism, and mitochondrial dysfunction
[22]. Thus, there is a link between pre-diabetes
and heart failure. A vast majority of individuals
with heart failure have stable IR, which, in turn,
correlates with the severity of the disease and
outcomes [23, 24]. Some years ago Ingelsson
et al. showed in a large population that IR is
correlated with the incidence of heart failure
independently of known risk factors, including
diabetes [25].
In the setting of heart failure, the reduced
cardiac output and increased adrenergic
activation, both of which are responsible for
sub-optimal tissue perfusion, could lead to IR
and impaired glucose tolerance. Nevertheless,
insulin-resistant overt cardiomyopathy has
been described in relation to an inefficiency in
myocardial energy [26].
IR determines energy inadequacy in
cardiomyocytes due to an increased recourse
to fatty acids, which are energetically less
efficient than glucose. Furthermore, in
contrast to those in healthy subjects, the
cardiomyocytes of patients with IR are not
able to use glucose under conditions of stress.
These mechanisms, which are associated with
endothelial impairment in IR patients, may
Table 1 Baseline clinical characteristics of the entire study
population (n = 75)
Characteristic Mean – SDa
Age (years) 46.2 ± 11
Height (cm) 167.2 ± 9
Weight (kg) 83.3 ± 11
BMI (kg/m2) 29.8 ± 4.1
Fasting glucose (mg/dL) 112 ± 14
Fasting insulin (lU/mL) 23.7 ± 14.1
HOMA index 5.48 ± 3.8
Total cholesterol (mg/dL) 206 ± 14
HDL (mg/dL) 52 ± 10
LDL (mg/dL) 131 ± 24






IGT ? IFG 22
Diabetes 0
CPET parameters
Peak VO2 (mL/kg/min) 20.16 ± 3.72
% 61.83 ± 12
VO2 (L/min) 1.70 ± 0.41
% 73.6 ± 12.3
Work (watts) 114.6 ± 31
AT (L/min) 1.01 ± 0.25
AT% peak VO2 48.1 ± 11
VO2/work 9.7 ± 1.36
AT anaerobic threshold, BMI body mass index, CPET cardiopulmonary
exercise test, HDL high-density lipoprotein, HOMA homeostasis model
assessment, IFG impaired fasting glycemia, IGT impaired glucose
tolerance, LDL low-density lipoprotein, NG normal glycemic subjects,
SD standard deviation, VO2 oxygen consumption, % VO2 in percentage
compared to normal values
a Unless otherwise stated
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contribute to the reduction of both
cardiopulmonary performance [9] and
myocardial contractile reserves [13, 14].
MET and IR
One treatment option for pre-diabetic patients
is the biguanide MET. In diabetic patients, MET
has been associated with improved outcomes
[27]. In the US DPP, MET was demonstrated to
reduce the evolution from a condition of
glucose intolerance to diabetes [28, 29]. A
beneficial effect on systolic function after
3 months of MET therapy has been previously
described in animal models of heart failure, in
which it was demonstrated that administration
of the drug provides significant
cardio-protective effects and improves LV
function [30, 31]. In patients with heart
failure, the use of MET was shown to cause an
increase in systolic function with better
outcomes compared to other treatments [32,
33]. Wong et al. recently demonstrated a
positive effect of MET treatment on LV
function in IR patients with advanced heart
failure [34]. They showed that LVEF recovers
only when the treatment with MET is
accompanied by a decrease in brain natriuretic
peptide, thereby suggesting that MET may
improve systolic function by decreasing
cardiac overload. The present study, using the
reliable STE technique, confirmed the ability of
MET to significantly improve LV systolic
function in an IR population.
The detailed mechanisms by which MET
exerts its beneficial effects appear to be related
to a decrease in free fatty acid levels, reduction
of myocardial lipid accumulation, diminished
perivascular fibrosis, and AMPK-eNOS signal
activation [30]. However, MET has several
limitations concerning its use, and various
adverse events have been reported. MET may








Age (years) (mean ± SD) 47.1 ± 11 45.5 ± 12 46.0 ± 12
Weight (kg) (mean ± SD) 84.3 ± 10 83.5 ± 13 82.1 ± 11
BMI (kg/m2) (mean ± SD) 28.3 ± 4.5 30.1 ± 3.2 31.0 ± 4.6
HOMA index (mean ± SD) 6.07 ± 4.5 5.71 ± 3.8 4.67 ± 4.2
PeakVO2 (L/min) 1.96 ± 0.38 1.54 ± 0.50 1.60 ± 0.38
Risk factor n (%)
Smoking 4 (16) 5 (20) 5 (20)
Hypertension 9 (36) 8 (32) 12 (48)
Hypercholesterolemia 7 (28) 6 (24) 8 (32)
CAD 0 0 0
PAD 0 0 0
BMI body mass index, CAD coronary artery disease, PAD peripheral artery disease, SD standard deviation, VO2 oxygen
consumption
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cause a decrease in VO2 in subjects with no IR
[8], and our previous data have demonstrated
the same effect in patients with IR [9]. It is of
importance that this effect does not occur in
every patient but mainly in those with a lower
degree of IR; in contrast, CP performance is
significantly increased in subjects with a high
degree of IR. In patients with heart failure, MET
significantly improves IR and the pulmonary
ventilation/ventilator carbon dioxide slope,
leading to significant weight loss; however, it
is unable to increase the peak VO2 [34].
The Association Between Physical
Training and MET in IR
Regular exercise increases the peripheral
sensitivity to insulin mainly of skeletal muscle,
largely by stimulating AMPK [35, 36]. The
American Diabetes Association strongly
recommends exercise as a cornerstone therapy
for the prevention of diabetes, and the
combination of exercise and MET has been
proposed in place of each of the two separate
therapies [17]. Currently available data suggest
an advantage of the addition of metformin to
physical training in terms of weight loss [37] but
negligible or no effect on IR [38]. Insulin
sensitivity in pre-diabetic subjects can be
increased by physical exercise, but the
association with MET does not determine a
further advantage in terms of sensitivity to the
hormone and can even attenuate the effect of
the physical training [10].
In a previous study, we showed that the
association with physical training could
compensate the negative effects of MET on
cardiopulmonary performance. Furthermore,
we demonstrated that physical exercise, when
personalized and supervised, affected
cardiopulmonary parameters and quality of
life similar to the combination of MET and
exercise [11]. Moreover, there are limited data
for the effect of physical training alone or in
combination with MET on LV cardiac function.
Stewart et al. showed that 6 months of exercise
had no effect on cardiac dimensions or on LV
diastolic function despite a significant increase
in cardiopulmonary performance in terms of
peak VO2 [39].
To our knowledge, the present results show
for the first time that physical training alone
does affect LV cardiac function despite the
improvements in cardiopulmonary
performance. However, the association
between supervised exercise and MET does not
reduce the positive effects of the drug on the
indices of LV systolic function and retains its
positive influence on exercise capacity in terms
of peak VO2. At present, however, it remains
unknown whether the beneficial effects on the
indices of myocardial performance at rest can be
Table 3 Echocardiographic data for the entire study
population (n = 75)
Parameter Mean – SD
EDD (mm) 47.45 ± 4.34
EDV (mL) 80.62 ± 20.32
Left ventricular mass (g) 145.47 ± 5.68
EF (%) 66.67 ± 4.99
LAA (cm2) 18.56 ± 3.45
DcT (s) 0.195 ± 0.05
IVRT (s) 0.11 ± 0.06
E/E0 9.51 ± 3.65
S wave (cm/s) 7.11 ± 1.13
GLS (%) 24.6 ± 10.8
DcT E wave deceleration time, EDD end-diastolic
diameter, EDV end-diastolic volume, E/E0 E wave peak
velocity/E0 wave peak velocity ratio, EF left ventricular
ejection fraction, GLS global longitudinal strain, GLSR
global longitudinal strain rate, IVRT iso-volumic relaxation
time, LAA left atrium area, SD standard deviation
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Table 4 Differences in echocardiographic parameters between pre- and post-treatment
Parameter Treatment group (mean – SD)
Metformin
n 5 25




EDD (mm) -1.78 ± 1.21 1.60 ± 1.49 0.82 ± 1.22
IVS (mm) 0.46 ± 15.14 -1.68 ± 16.79 0.37 ± 16.98
Left ventricular mass (g) -4.69 ± 28.00 -5.4 ± 29.21 -6.06 ± 16.99
EDV (mL) -4.68 ± 15.15 1.45 ± 9.86 3.49 ± 11.54
EF (%) 0.68 ± 3.61 -4.23 ± 5.16 -1.88 ± 4.12
IVRT (s) 0.00 ± 0.04 -0.01 ± 0.04 0.00 ± 0.06
E/E0 -0.65 ± 1.25 -0.57 ± 1.27 -0.45 ± 1.32
S wave (cm/s) 0.82 ± 4.65a 1.07 ± 3.84a -0.08 ± 3.39
GLS (%) 9 ± 5a 15 ± 7a -2 ± 4.7
GLSR (s-1) 0.53 ± 0.41a 0.55 ± 0.59a 0.05 ± 0.39
EDD end-diastolic diameter, EDV end-diastolic volume, E/E0 E wave peak velocity/E0 wave peak velocity ratio, EF left
ventricular ejection fraction, Ex exercise training group, GLS global longitudinal strain, GLSR global longitudinal strain rate,
IVRT iso-volumic relaxation time, IVS inter-ventricular septum, SD standard deviation
a P\0.05 vs Ex
Table 5 Echocardiographic parameter data pre- and post-treatment
Parameter Treatment group, mean – SD
Metformin n5 25 Metformin1 exercise training
n5 21
Exercise training n5 20
Pre Post Pre Post Pre Post
EDD (m) 47.34 ± 3.33 45.56 ± 5.55 46.90 ± 5.94 48.50 ± 4.71 47.56 ± 5.30 48.38 ± 4.98
IVS (mm) 8.61 ± 0.97 9.07 ± 1.51 10.13 ± 2.09 8.45 ± 1.50 7.95 ± 1.20 8.32 ± 0.778
MASS (g) 145.82 ± 31.80 141.13 ± 47.69 144.40 ± 35.15 139.00 ± 24.45 147.56 ± 15.01 141.5 ± 23.44
EDV (mL) 71.66 ± 14.55 66.98 ± 11.45 78.41 ± 21.13 79.86 ± 14.11 75.40 ± 15.20 78.89 ± 13.00
EF (%) 66.77 ± 4.60 67.45 ± 6.72 68.73 ± 8.94 64.50 ± 7.46 67.54 ± 8.34 65.66 ± 7.34
IVRT (s) 0.07 ± 0.02 0.07 ± 0.02 0.09 ± 0.02 0.08 ± 0.02 0.08 ± 0.02 0.08 ± 0.02
E/E0 8.65 ± 2.89 9.30 ± 2.23 9.00 ± 0.73 8.43 ± 1.32 8.26 ± 0.66 7.81 ± 0.97
S wave (cm/s) 6.95 ± 1.24 7.77 ± 0.87a 6.96 ± 1.34 7.97 ± 0.94a 7.43 ± 1.56 7.35 ± 0.91
GLS (%) 27 ± 12 36 ± 13a 22 ± 10 37 ± 11a 24 ± 11 22 ± 10
GLSR s-1 1.10 ± 0.50 1.63 ± 0.57a 1.31 ± 0.59 1.86 ± 0.6 a 0.83 ± 0.14 0.88 ± 0.12
EDD end-diastolic diameter, EDV end-diastolic volume, E/E0 E wave peak velocity/E0 wave peak velocity ratio, EF left
ventricular ejection fraction, Ex exercise training group, GLS global longitudinal strain, GLSR global longitudinal strain rate,
IVRT iso-volumic relaxation time, IVS inter-ventricular septum, MASS left ventricular mass, SD standard deviation
a P\0.05 vs Pre-treatment
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preserved during physical activity in terms of
contractile reserve and cardiac performance.
In agreement with the results of previous
studies, we did not observe any improvement in
the indices of diastolic function after physical
training [39], or even after MET alone or in
combination with exercise. Moreover, a
beneficial effect of MET on diastolic function
was recently hypothesized and proposed as a
rational endpoint in a randomized trial [40].
Limitations
The main limitation of the study is related to
the study design. A single-blinded design was
chosen due to the difficulties of concealing the
exercise aspect of treatment. Moreover, patients
were not randomized to a treatment group and
rather were allocated a treatment based on
consecutive enrollment to the study.
CONCLUSION
The primary purpose of this study was to assess
the potential advantages of the association
between physical training and the
administration of MET on LV function in
individuals with IR. Although exercise is
currently recommended as a cornerstone
therapy for the prevention of diabetes, adding
MET has not been shown to improve
cardiopulmonary performance or sensitivity to
insulin.
Our results demonstrate that the
combination of MET and physical training
improves LV myocardial function in IR
patients. Given the known positive effect on
cardiopulmonary function of adding physical
exercise to MET, these findings suggest the
advantage of the combination of
pharmacological and physical therapy to ward
off the multiple adverse effects of insulin
resistance on cardiovascular function.
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